Eli Lilly: The Stock Might Have Peaked

Summary:

• Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors.
• But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound.
• Nevertheless, the stock seems expensive — also when compared to Novo Nordisk — and we should be very cautious about an investment.

When looking for mistakes I made in the past, it is not difficult in more than 750 available articles about more than 100 different companies to find huge mistakes. Everybody is making mistakes – including me. And one article

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.